DiaSorin's 4% Q2 Growth Looks Better Than the 15% Profit Drop-For Now

Q2 improved the sales pace, but profitability is still the real test

What changed this week is the pace, not the proof. DiaSorin's Q2 revenue rose 4% at constant rates, and management said that puts it back on track for both the expected quarterly progression and full-year guidance confirming expected quarterly progression and full-year guidance. That matters because investors were testing whether Q1's stumble was a one-off. But this is still not a celebratory quarter. The more important question is whether the sales recovery is translating into cleaner profit conversion.

On that score, the first-half picture is mixed. Net profit for H1 2026 was €84 million, down 15% year-over-year, with adjusted net profit at €106 million (18% of revenue). Gross margin held at 65%, and Q2 EBITDA margin improved to 33%, but H1 EBITDA still came in at 32%. In other words, growth is back, but the earnings recovery is still incomplete.

Why the mixed signal matters

DiaSorin is not broken. The core market is still there, gross margin remained resilient, and the business resumed growth. But the profit squeeze shows that growth still has to be earned. Management pointed to pricing pressure in China and increased U.S. commercial investments as headwinds. That means part of the sales effort is being offset by a tougher China environment and by higher commercial spending in the U.S.

That makes the story more interesting, not less-but only if the next phase converts sales momentum into better profitability. The case improves materially if the U.S. immunodiagnostics recovery and Liaison Plex adoption start showing up more clearly in margins and cash generation. Until then, this is a "growth is back, but so is the grind" story.

U.S. immunodiagnostics and Plex adoption are the strongest parts of the recovery

The Q2 sales improvement matters, but the better question is whether it rests on a repeatable business model.

Why the U.S. story matters most

The bull case is not that everything is recovering. It is that DiaSorin's largest market is starting to grow from assets that can keep generating reagent demand. Management said the U.S. immunodiagnostics business returned to historical double-digit growth, helped by the recovery of QuantiFERON sales and an active hospital campaign aimed at 600 hospitals by end of 2026. That is the kind of setup investors want to see early.

Machines on site do not just create a one-time equipment sale. They can build an installed base that keeps pulling in consumables, assuming the platform remains useful and the sales force keeps opening doors.

The platform mix matters more than the headline growth rate

The more interesting tell is where new customers are going. DiaSorin says the Liaison Plex platform is gaining strong market traction, with over 150 customers and the vast majority of new placements choosing the Flex configuration. That suggests new business is leaning toward the newer setup rather than simply defending older habits.

If that mix shift holds, DiaSorin could improve the quality of that business over time because newer platforms can support stronger customer retention and better reagent pull-through.

There is also support outside the core U.S. immunodiagnostics engine. The Luminex business, or LTG, grew 7% in Q2, and management said it remains confident in mid-to-high single-digit growth for the year.

This is still a selective recovery

This is not yet a clean "all engines go" quarter. Immunodiagnostics rose 4% at CER, while Molecular Diagnostics rose just 1% at CER, so part of the portfolio remains sluggish. The rebound is still narrow.

But selective recovery can still be constructive if the stronger part of the business is the part with the biggest installed base and the best reagent tail. For now, that is where the bullish case sits.

The key watch items are simple: whether new platform placements continue to favor Flex, whether the hospital push keeps expanding the installed base, and whether that translates into steadier profitability.

China and U.S. spending are still limiting the margin case

The market can forgive slower growth if the profit mix is improving. It is less likely to reward DiaSorin while margins are still being pulled down by a China business that continues to decline roughly 25% and increased U.S. commercial investments. That is why the 32% EBITDA margin in H1 still matters: investors do not need another reminder that growth has returned; they need proof that each extra euro of sales is keeping more of itself.

Why margin recovery is still fragile

China remains the clearest drag. Management linked that weakness to VBP pricing and local competition, and it said there is no expected improvement in H2. That matters because a market still losing roughly a quarter of its size can keep suppressing consolidation even if the rest of the portfolio heals.

The U.S. side is the other pressure point. The same commercial push behind the hospital strategy and Liaison Plex rollout is helping revenue, but those investments are still showing up as a margin headwind through higher U.S. commercial spending. In plain English, DiaSorin is spending to widen the installed base before the full profit payoff arrives.

What would change the narrative

H2 expected to benefit from normalized flu season, NES and PLEX system rollouts, and improved cash generation as inventory levels normalize. If that happens, the market has a more concrete reason to look past the current earnings squeeze.

The main risk is that China stays soft, U.S. spending continues to press on profit, or molecular growth does not begin to accelerate. In that case, the stock may remain trapped in a "growth is back, but the grind is not over" pattern.